Tandem Diabetes Care Appoints New Senior Vice President to Drive Expansion of Digital Health and Information Technology Initiatives

SAN DIEGO–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24TNDM&src=ctag” target=”_blank”gt;$TNDMlt;/agt; lt;a href=”https://twitter.com/hashtag/TNDM?src=hash” target=”_blank”gt;#TNDMlt;/agt;–Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery
and diabetes technology company, today announced the appointment of
Manuel Jaime as its new Senior Vice President, Technology and Digital
Health. Jaime will lead all activities related to information
technology, data management and security, data analytics, and
mobile/connected health solutions.

“Globalization of our data management applications, development of
robust connected health solutions, and maintaining the security of
customer and company data are key to our ability to provide a
revolutionary customer experience to our growing customer base and
distribution partners worldwide,” said Kim Blickenstaff, president and
CEO of Tandem Diabetes Care. “Manuel has been a pioneer in these areas,
with broad-based experience that we believe will enhance our customer
offerings, improve internal efficiencies and help further establish our
position as a leader in digital health in the diabetes community.”

“Leveraging leading edge technologies to deliver exceptional customer
experiences has been a focus throughout my career, which aligns well
with Tandem’s vision and philosophy,” said Jaime. “What Tandem has
accomplished in such a short period of time for people impacted by type
1 diabetes is incredible. I look forward to applying my technology
expertise to help take these efforts to the next level.”

Jaime is an accomplished technology executive with more than 20 years of
experience in incubating and commercializing emerging products and
services in the high-tech industry. He has spearheaded technology
development, product management, and technology strategy and planning at
startups and established companies. Jaime was most recently Chief
Technology Officer at Cedar Electronics, a leader in the field of driver
awareness, communications and information systems. He was also a
co-founder and Chief Executive Officer of ClipCast Technologies, and he
previously held various roles at CardioNet and Qualcomm. He also is an
inventor on more than 20 patents relating to connected devices, wireless
systems, video platforms, and low-power radio frequency. Jamie is a
graduate of the Leaders for Global Operations (LGO) Program at the
Massachusetts Institute of Technology (MIT) Sloan School of Management
where he received an MBA and a MS in Mechanical Engineering. He also
holds a BS in Mechanical Engineering and a MS in Systems Engineering
from MIT.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach to
the design, development and commercialization of products for people
with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™
insulin pump, is capable of remote software updates using a personal
computer and features integrated continuous glucose monitoring. Tandem
is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslimX2 and
$TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow
Tandem Diabetes Care on LinkedIn at www.linkedin.com/company/TandemDiabetes.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a
trademark of Tandem Diabetes Care, Inc.

Forward Looking Statement

This press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
relate to, among other things, the anticipated future growth of the
Company and the Company’s goals to enhance product offerings, improve
internal efficiencies and be leader in digital health in the diabetes
community. These statements are subject to numerous risks and
uncertainties, including our ability to obtain regulatory approval for
new products and products under development and the timing of any such
approvals; market acceptance of the Company’s existing products and
products under development by physicians and people with diabetes; the
Company’s ability to establish and sustain operations to support
international sales; the Company’s ability to meet increasing
operational and infrastructure requirements from higher customer
interest and a larger base of existing customers; as well as other risks
identified in our most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, and other documents that we file with the
Securities and Exchange Commission. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date of this release. Tandem undertakes no obligation to update
or review any forward-looking statement in this press release because of
new information, future events or other factors.

Contacts

Media:
Steve Sabicer
714-907-6264
[email protected]

Investors:
Susan Morrison
858-366-6900 x7005
[email protected]

error: Content is protected !!